Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05136755 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 2024 to Nov 2026
    • Study completion date: Dec 2024 to Dec 2026
    v5
  2. 2 versions Re-verified since Feb 7, 2023, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 2021 to Jan 25, 2022
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Trial Details
NCT Number NCT05136755
Lead Sponsor China Medical University Hospital
Conditions
(from sponsor)		 Major Depressive Disorder
Related terms Major Depressive Disorder
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov